Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITAZAREM: Rituximab vs Azathioprine as Maintenance in Relapsing ANCA-associated Vasculitis
NCT01697267Phase 3Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Apr 2013
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Apr 2013; status: completed.
02
Drugs
rituximab
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)microscopic polyangiitis (MPA)granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on NCT01697267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01697267.